僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Elezanumab （ABT-555; AE12-1Y-QL） is a human monoclonal antibody that selectively targets repulsive guidance molecule A （RGMa）. Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism